Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | PARL | Q9H300 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11932224 | 0.91 | HTR2A (0.45) | HTR2ATDP1ATMALDH1A1MAPT | |
| SCHEMBL12237288 | 0.87 | CHRM5 (0.44) | TDP1ATMPARL | |
| SCHEMBL1578918 | 0.82 | ALDH1A1 (0.48) | TDP1ALDH1A1MAPTPARLSMN1; SMN2 | |
| SCHEMBL2454828 | 0.81 | HTR2A (0.45) | HTR2ATDP1ATMALDH1A1MAPT | |
| SCHEMBL37664 | 0.81 | HTR2A (0.62) | HTR2AALDH1A1RAB9AIDO1AKR1C3 | |
| SCHEMBL2208957 | 0.80 | MGLL (0.44) | MAPTRAB9APOLBSMN1; SMN2 | |
| SCHEMBL5357731 | 0.80 | NAAA (0.43) | TDP1ALDH1A1MAPTPOLB | |
| SCHEMBL5354116 | 0.80 | NAAA (0.43) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL13065050 | 0.80 | CCNE1 (0.36) | HPGD | |
| SCHEMBL1992162 | 0.80 | MGLL (0.45) | ALDH1A1MAPTRAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592436-A4 | COMPOUNDS THAT BIND P2Y sb 2 /sb OR P2Y sb 1 /sb RECEPTORS | KIMBERLY CLARK CO (US) | 2009-09-02 | — | — | EP | claimed |
| US-7056889-B2 | Compounds that bind P2Y2 or P2Y1 receptors | KIMBERLY-CLARK, WORLDWIDE, INC. (US) | 2006-06-06 | — | — | US | claimed |
| EP-1592436-A2 | COMPOUNDS THAT BIND P2Y sb 2 /sb OR P2Y sb 1 /sb RECEPTORS | Kimberly-Clark Worldwide, Inc. (US) | 2005-11-09 | — | — | EP | claimed |
| WO-2004060907-A2 | COMPOUNDS THAT BIND P2Y2 OR P2Y1 RECEPTORS | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2004-07-22 | — | — | WO | claimed |
| US-20040116339-A1 | Compounds that bind P2Y2 or P2Y1 receptors | KIMBERLY-CLARK WORLDWIDE, INC. | 2004-06-17 | — | — | US | claimed |
| US-11117915-B2 | Antibacterial aminoglycoside analogs | Cipla USA, Inc. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200317709-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2020-10-08 | — | — | US | disclosed |
| US-RE47741-E1 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2019-11-26 | — | — | US | disclosed |
| US-20170210778-A1 | NOVEL COMPOUNDS | INVIVOGEN SAS (FR) | 2017-07-27 | — | — | US | disclosed |
| US-9688711-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688711-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| EP-3169698-A1 | NOVEL COMPOUNDS | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of Holy and Undiv. Trinity of Queen Elizabeth near Dublin (IE) | 2017-05-24 | — | — | EP | disclosed |
| EP-1959968-A2 | MODULATION OF THE P2Y2 RECEPTOR PATHWAY | P2-Science APS (DK) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007065437-A2 | MODULATION OF THE P2Y2 RECEPTOR PATHWAY | P2-SCIENCE APS (DK) | 2007-06-14 | — | — | WO | disclosed |
| US-7056889-B2 | Compounds that bind P2Y2 or P2Y1 receptors | KIMBERLY-CLARK, WORLDWIDE, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1592436-A2 | COMPOUNDS THAT BIND P2Y sb 2 /sb OR P2Y sb 1 /sb RECEPTORS | Kimberly-Clark Worldwide, Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004060907-A2 | COMPOUNDS THAT BIND P2Y2 OR P2Y1 RECEPTORS | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040116339-A1 | Compounds that bind P2Y2 or P2Y1 receptors | KIMBERLY-CLARK WORLDWIDE, INC. | 2004-06-17 | — | — | US | disclosed |
| EP-0451519-B1 | Process for the preparation of N-succinimidylcarbonates | CHEMIE LINZ GMBH (AT) | 1994-12-14 | — | — | EP | disclosed |
| EP-0451519-A1 | Process for the preparation of N-succinimidylcarbonates | Chemie Linz GmbH (AT) | 1991-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317709-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | HTR2A 3339/4885TDP1 2209/4885ATM 2071/4885 |
| US-11117915-B2 | Antibacterial aminoglycoside analogs | MRPL21, MRPL9, NQO2 | HTR2A 3339/4885TDP1 2209/4885ATM 2071/4885 |
| US-20170210778-A1 | NOVEL COMPOUNDS | F12, C1R, F11 | HTR2A 3356/4885TDP1 2951/4885ATM 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.